Mortality Risk of Hypnotics: Strengths and Limits of Evidence

Drug Safety

Volumn 39, Issue 2, 2016, Pages 93-107

  Kripke, Daniel F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DIPHENHYDRAMINE; HYPNOTIC AGENT; SEDATIVE AGENT; HYPNOTIC SEDATIVE AGENT;

ARTICLE; BIBLIOGRAPHIC DATABASE; CAUSE OF DEATH; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG INTOXICATION; DRUG METABOLISM; ELECTRONIC MEDICAL RECORD; FOLLOW UP; GENETIC POLYMORPHISM; HAZARD RATIO; HEREDITY; HUMAN; INFECTION; INSOMNIA; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NEOPLASM; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; TIME OF DEATH; ANIMAL; EPIDEMIOLOGY; ODDS RATIO; TRENDS;

ANIMALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); HUMANS; HYPNOTICS AND SEDATIVES; MORTALITY; ODDS RATIO; RISK FACTORS;

EID: 84956954228     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0362-0     Document Type: Article

References (86)

1. Hammond EC. Some preliminary findings on physical complaints from a prospective study of 1,064,004 men and women. Am J Public Health. 1964;54:11–24.
2. Kripke DF, Simons RN, Garfinkel L, Hammond EC. Short and long sleep and sleeping pills: Is increased mortality associated? Arch Gen Psychiatry. 1979;36(1):103–16.
3. Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription hypnotics. Biol Psychiatry. 1998;43(9):687–93.
4. Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry. 2002;59(2):131–6.
5. Jaussent I, Ancelin ML, Berr C, Peres K, Scali J, Besset A, et al. Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Med. 2013;11(1):212.
6. NIOM. Sleeping pills, insomnia, and medical practice. Washington, DC: National Academy of Sciences; 1979.
7. National Institutes of Health State of the Science. Conference statement on manifestations and management of chronic insomnia in adults, June 13–15, 2005. Sleep. 2005;28(9):1049–57.
8. Saras A, Gisselmann G, Vogt-Eisele AK, Erlkamp KS, Kletke O, Pusch H, et al. Histamine action on vertebrate GABAA receptors: direct channel gating and potentiation of GABA responses. J Biol Chem. 2008;283(16):10470–5.
9. Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996.
10. Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2(1):e000850.
11. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–83.
12. Kojima M, Wakai K, Kawamura T, Tamakoshi A, Aoki R, Lin Y, et al. Sleep patterns and total mortality: a 12-year follow-up study in Japan. J Epidemiol. 2000;10(2):87–93.
13. Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2012;68(2):163–70.
14. Neutel CI, Johansen HL. Association between hypnotics use and increased mortality: causation or confounding? Eur J Clin Pharmacol. 2015;71(5):637–42.
15. Mallon L, Broman JE, Hetta J. Is usage of hypnotics associated with mortality? Sleep Med. 2009;10(3):279–86.
16. Belleville G. Mortality hazard associated with anxiolytic and hypnotic drug use in the national population health survey. Can J Psychiatry. 2010;55(9):558–67.
17. Chen H-C, Su T-P, Chou P. A 9-year follow-up study of sleep patterns and mortality in community-dwelling older adults in Taiwan. Sleep. 2013;36(8):1187–98.
18. Ford ES, Wheaton AG, Cunningham TJ, Giles WH, Chapman DP, Croft JB. Trends in outpatient visits for insomnia, sleep apnea, and prescriptions for sleep medications among US adults: findings from the National Ambulatory Medical Care Survey 1999–2010. Sleep. 2014;37(8):1283–93.
19. Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999–2010. Sleep. 2014;37(2):343–9.
20. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985;42:225–32.
21. Kripke DF, Garfinkel L. Excess nocturnal deaths related to sleeping pill and tranquilliser use. Lancet. 1984;I(8368):99.
22. Gagliardi GS, Shah AP, Goldstein M, Denua-Rivera S, Doghramji K, Cohen S, et al. Effect of zolpidem on the sleep arousal response to nocturnal esophageal acid exposure. Clin Gastroenterol Hepatol. 2009;7(9):948–52.
23. Kripke DF. Hypnotics cause insomnia: evidence from clinical trials. Sleep Med. 2014;15(9):1168–9.
24. Kripke DF. Greater incidence of depression with hypnotics than with placebo. BMC Psychiatry. 2007;7:42.
25. Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med. 2009;5(4):377–83.
26. Kripke DF. Possibility that certain hypnotics might cause cancer in skin. J Sleep Res. 2008;17(3):245–50.
27. Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf. 2006;1(1):63–71.
28. Verster JC, Roth T. Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality. Psychopharmacology (Berl). 2011;219(3):775–81.
29. Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, et al. On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers. Sleep. 2015. (Epub ahead of print).
30. Hansen RN, Boudreau DM, Ebel BE, Grossman DC, Sullivan SD. Sedative hypnotic medication use and the risk of motor vehicle crash. Am J Public Health. 2015;105(8):e64–9. doi:10.2105/AJPH.2015.302723.
31. Philip P, Chaufton C, Orriols L, Lagarde E, Amoros E, Laumon B, et al. Complaints of poor sleep and risk of traffic accidents: a population-based case–control study. PLoS One. 2014;9(12):e114102. doi:10.1371/journal.pone.0114102.
32. Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther. 2011;89(4):595–601.
33. Diem SJ, Ewing SK, Stone KL, Ancoli-Israel S, Redline S, Ensrud KE. Use of non-benzodiazepine sedative hypnotics and risk of falls in older men. J Gerontol Geriatr Res. 2014;3(3):158.
34. Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013;173(9):754–61.
35. Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med. 2013;8(1):1–6.
36. Huang CY, Chou FH, Huang YS, Yang CJ, Su YC, Juang SY, et al. The association between zolpidem and infection in patients with sleep disturbance. J Psychiatr Res. 2014;54(7):116–20.
37. Kao CH, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, et al. Benzodiazepine use possibly increases cancer risk: a population-based retrospective cohort study in Taiwan. J Clin Psychiatry. 2012;73(4):e555–60. doi:10.4088/JCP.11m07333.
38. Kao CH, Sun LM, Liang JA, Chang SN, Sung FC, Muo CH. Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study. Mayo Clin Proc. 2012;87(5):430–6.
39. Sivertsen B, Salo P, Pentti J, Kivimaki M, Vahtera J. Use of sleep medications and risk of cancer: a matched case-control study. Sleep Med. 2015. doi:10.1016/j.sleep.2015.05.003. (Epub ahead of print).
40. Lawlor DA, Nordestgaard BG, Benn M, Zuccolo L, Tybjaerg-Hansen A, Davey SG. Exploring causal associations between alcohol and coronary heart disease risk factors: findings from a Mendelian randomization study in the Copenhagen General Population Study. Eur Heart J. 2013;34(32):2519–28.
41. Au Yeung SL, Jiang C, Cheng KK, Liu B, Zhang W, Lam TH, et al. Is aldehyde dehydrogenase 2 a credible genetic instrument for alcohol use in Mendelian randomization analysis in Southern Chinese men? Int J Epidemiol. 2013;42(1):318–28.
42. Hublin C, Partinen M, Koskenvuo M, Kaprio J. Heritability and mortality risk of insomnia-related symptoms: a genetic epidemiologic study in a population-based twin cohort. Sleep. 2011;34(7):957–64.
43. Wing YK, Zhang J, Lam SP, Li SX, Tang NL, Lai KY, et al. Familial aggregation and heritability of insomnia in a community-based study. Sleep Med. 2012;13(8):985–90.
44. Boef AG, Dekkers OM, le Cessie S. Mendelian randomization studies: a review of the approaches used and the quality of reporting. Int J Epidemiol. 2015;44(2):496–511.
45. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89–98.
46. Burgess S, Daniel RM, Butterworth AS, Thompson SG. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol. 2015;44(2):484–95.
47. Thanassoulis G. Mendelian randomization: how genetics is pushing the boundaries of epidemiology to identify new causes of heart disease. Can J Cardiol. 2012;29(1):30–6.
48. Lopez-Munoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat. 2005;1(4):329–43.
49. Leary S, Members of Panel. AVMA Guidelines for the Euthanasia of Animals: 2013 Edition. 2013.0.1 ed. Schaumburg:American Veterinary Medical Association;2013.
50. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case–cohort study. BMJ. 2015;350:h2698. doi:10.1136.bmj.h2698.
51. Jann M, Kennedy WK, Lopez G. Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract. 2014;27(1):5–16.
52. Cooper JR. Sedative-hypnotic drugs: risks and benefits. Rockville: U.S. Department of HEW, National Inst. on Drug Abuse; 1977.
53. Rockett IR. Self-injury is the eighth leading cause of death in the United States: it is time to pay attention. JAMA Psychiatry. 2015;72(11):1069–70. doi:10.1001/jamapsychiatry.2015.1418.
54. Nobody. The DAWN report: Benzodiazepines in combination with opioid pain relievers or alcohol: greater risk of more serious ED visit outcomes. DAWN-192. Rockville:Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality;2014.
55. Okamoto M, Rao SN, Aaronson LM, Walewski JL. Ethanol drug interaction with chlordiazepoxide and pentobarbital. Alcohol Clin Exp Res. 1985;9(6):516–21.
56. Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008;9(4):425–32.
57. Chung WS, Lai CY, Lin CL, Kao CH. Adverse respiratory events associated with hypnotics use in patients of chronic obstructive pulmonary disease: a population-based case-control study. Medicine (Baltimore). 2015;94(27):e1110.
58. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327(7429):1459–61.
59. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–8.
60. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012;13(1):40.
61. Lack L, Wright H, Paynter D. The treatment of sleep onset insomnia with bright morning light. Sleep Biol Rhythms. 2007;3:173–9.
62. Rumble R, Morgan K. Hypnotics, sleep, and mortality in elderly people. J Am Geriatr Soc. 1992;40:787–91.
63. Isacson D, Carsjo K, Bergman U, Blackburn JL. Long-term use of benzodiazepines in a Swedish community: an eight-year follow-up. J Clin Epidemiol. 1992;45(4):429–36.
64. Thorogood M, Cowen P, Mann J, Murphy M, Vessey M. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet. 1992;340:1067–8.
65. Brabbins CJ, Dewey ME, Copeland RM, Davidson IA, McWilliam C, Saunders P, et al. Insomnia in the elderly: prevalence, gender differences and relationships with morbidity and mortality. Int J Ger Psych. 1993;8:473–80.
66. Merlo J, Hedblad B, Ogren M, Ranstam J, Ostergren PO, Ekedahl A, et al. Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics-hypnotics and analgesics. Eur J Clin Pharmacol. 1996;49:261–5.
67. Hays JC, Blazer DG, Foley DJ. Risk of napping: excessive daytime sleepiness and mortality in an older community population. J Am Geriatr Soc. 1996;44:693–8.
68. Sundquist J, Ekedahl A, Johansson S-E. Sales of tranquillizers, hypnotics/sedatives and antidepressants and their relationship with underprivileged area score and mortality and suicide rates. Eur J Clin Pharmacol. 1996;51:105–9.
69. Merlo J, Ostergren PO, Mansson NO, Hanson BS, Ranstam J, Blennow G, et al. Mortality in elderly men with low psychosocial coping resources using anxiolytic-hypnotic drugs. Scand J Public Health. 2000;28(4):294–7.
70. Hedner J, Caidahl K, Sjoland H, Karlsson T, Herlitz J. Sleep habits and their association with mortality during 5-year follow-up after coronary artery bypass surgery. Acta Cardiol. 2002;57(5):341–8.
71. Mallon L, Broman J-E, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Int Med. 2002;251:207–16.
72. Ahmad R, Bath PA. Identification of risk factors for 15-year mortality among community-dwelling older people using Cox regression and a genetic algorithm. J Gerontol A Biol Sci Med Sci. 2005;60A:1052–8.
73. Phillips B, Mannino DM. Does insomnia kill? Sleep. 2005;28(8):965–71.
74. Lack LC, Prior K, Luszcz M. 708. Does insomnia kill the elderly? Sleep. 2006;29(Abstract Supplement):A240.
75. Fukuhara S, Green J, Albert J, Mihara H, Pisoni R, Yamazaki S, et al. Symptoms of depression, prescription of benzodiazepines, and the risk of death in hemodialysis patients in Japan. Kidney Int. 2006;70(10):1866–72.
76. Hausken AM, Skurtveit S, Tverdal A. Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiol Drug Saf. 2007;16(8):913–8.
77. Hoffmann VP, Dossenbach M, West TM, Lowry AJ. Mortality in a cohort of outpatients with schizophrenia: 3-year outcomes from the Intercontinental Outpatient Health Outcomes Study (IC-SOHO). Biol Psychiatry. 2007;61(8S):163S–164S. (Abstract).
78. Hublin C, Partinen M, Koskenvuo M, Kaprio J. Sleep and mortality: a population-based 22-year follow-up study. Sleep. 2007;30(10):1245–53.
79. Winkelmayer WC, Mehta J, Wang PS. Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney Int. 2007;72(11):1388–93.
80. Rod NH, Vahtera J, Westerlund H, Kivimaki M, Zins M, Goldberg M, et al. Sleep disturbances and cause-specific mortality: results from the GAZEL cohort study. Am J Epidemiol. 2010;173(3):300–9.
81. Gisev N, Hartikainen S, Chen TF, Korhonen M, Bell JS. Mortality associated with benzodiazepines and benzodiazepine-related drugs among community-dwelling older people in Finland: a population-based retrospective cohort study. Can J Psychiatry. 2011;56(6):377–81.
82. Hartz A, Ross JJ. Cohort study of the association of hypnotic use with mortality in postmenopausal women. BMJ Open. 2012;2. doi:10.1136/bmjopen-2012-001413.
83. Frandsen R, Baandrup L, Kjellberg J, Ibsen R, Jennum P. Increased all-cause mortality with psychotropic medication in Parkinson’s disease and controls: a national register-based study. Parkinsonism Relat Disord. 2014;20(11):1124–8.
84. Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, et al. Long-term prescription of opioids and/or benzodiazepines and mortality among HIV-infected and uninfected patients. J Acquir Immune Defic Synd. 2015;69(2):223–33.
85. Pinot J, Herr M, Robine JM, Aegerter P, Arvieu JJ, Ankri J. Does the prescription of anxiolytic and hypnotic drugs increase mortality in older adults? J Am Geriatr Soc. 2015;63(6):1263–5.
86. Nakafero G, Sanders RD, Nguyen-Van-Tam JS, Myles PR. Association between benzodiazepine use and exacerbations and mortality in patients with asthma: a matched case-control and survival analysis using the United Kingdom Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2015;24(8):793–802.